|The Fifth World PH Symposium|
Feb. 27- March 1, 2013
At 1,200, a tripling in size from fhe Fourth Symposium
We are not alone!
Let me start with a little history.
In 1973, a handful of physicians and researchers came together in Geneva, Switzerland for a first ever meeting to discuss pulmonary hypertension. The driving force was a small case series on elevated pulmonary artery pressures in otherwise healthy young individuals in the 1950s and 1960s; and the epidemic of anorexigenic-associated (appeite suppressant-associated) PAH in Europe. The meeting led to an improved classification for PH and – several years later, in 1980 – the NIH began a five year registry for PH, the first in the field. Analysis from that registry became a backbone of research for more than the next two decades.
That important meeting in Geneva, known as the World Health Organization (WHO) Conference on Primary Pulmonary Hypertension, was planned as a one-time event. However, a quarter of a centuy later, Dr. Stuart Rich and others argued for a second meeting. It was held in Evian, France in 1998 and established the pattern of meetings every five years…with meetings held in 2003 (Venice, Italy), 2008 (Dana Point, California) and 2013, last week (Nice, France).
Each meeting has grown. Each has systematically strengthened how physicians and researchers across the world can work with common understanding for more rapid progress in the field.
The first meeting I attended was the Fourth World PH Symposium in Dana Point in 2008. It was exciting then to see 400 physicians and researchers from around the world plan together. Coming to Nice last week, the view was astonishing. In five years the meeting had grown to 1,200 attendees.
It was a good feeling to hear Dr. Gerald Simmoneau open the Fifth World Symposium on the morning of February 27, speaking to the importance of the
patient associations across the world, specifically mentioning PHA and PHA Europe.
The Symposium Steering Committee was composed of five physicians from Europe and five from the U.S. Seven of the Steering Committee members were current or past members of PHA’s Scientific Leadership Council, four having served as chairs of that body.
The work of the Symposium had been developed by twelve Task Forces:
- Pathology & Pathobiology
- Genetics & Genomic
- Definitions & Classifications (and particularities of different PAH subgroups)
- Pathophysiology (focusing on exercise and RV)
- Epidemiology & Registries
- Diagnosis & Prognosis
- Therapy - Standard of Care
- Therapy - Goals
- New Trials Design & New Therapies
- PH due to Left Heart Diseases and Chronic Lung Diseases
- Pediatric PH
Over the course of three days each Task Force delivered their program, presenting the results of their work and their recommendations to the 1,200 participants. In each case, the presentations were followed by discussion and debate. Many of the presenters asked questions and the audience used electronic response devices to vote their responses. It was a great process of involvement and the task Forces will be reviewing the audience response before finalizing their recommendations over the next several weeks. Since this was the first time that a Pediatric Task Force was included, we are particularly interested in seeing their final report.
|PHA's poster presented at the World |
PH Symposium (primary author,
Dr. Sean Studer)
PHA and PHA Europe were provided with exhibit booths and it was so good to reconnect with our friends from PHA Europe as well as leaders from PHA Japan and PHA Israel. Our International community continues to grow. Melanie Gallant-Dewavrin, who I first met at PHA’s International Conference in 2000, told me that the HTAPFrance was founded in 1996 by Nicole Cabon after she attended PHA’s International conference in Stone Mountain, Georgia. That was the third PH association in the world (the German PH association, PHeV, was founded shortly before). Today there are over 60 (the Indian PH association website was just announced to the world PH community today!)
We were pleased to have an opportunity to present our poster and study on patient depression and anxiety. Since it came out after the European study, which PHA Europe also presented at the Symposium, we were able to include comparative data between the US and Europe in our material.
Last week was a great experience and the Fifth World PH Symposium is ended. Now we await the final reports but one thing is already very, very clear: PH may be a rare disease but it no longer exists in a dark corner. There is a spotlight shining on it and only good can come of that.